Overview
- Researchers from the University of Hong Kong emulated a target trial using the IMRD‑UK primary‑care database, studying adults with type 2 diabetes aged 25 to 84 over as long as 10 years.
- Initiating statins was associated with lower all-cause mortality and fewer major cardiovascular events across the full range of predicted 10‑year risk, including patients classified as low risk.
- The analysis focused on primary prevention, comparing new statin users with similar nonusers who had no serious heart or liver disease at baseline.
- Safety findings showed no increased risk of liver problems and only a very small increase in myopathy observed in one risk group.
- The peer-reviewed results were published in Annals of Internal Medicine, with authors urging clinicians to weigh the benefits even for patients with low short‑term cardiovascular risk.